Tumor liberated protein from lung cancer and perspectives for immunotherapy

Journal of Cellular Physiology

Volumn 221, Issue 1, 2009, Pages 26-30

  Tarro, Giulio ^a,b,c  

^a Temple University   (United States)

^b UNESCO   (France)

^c NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR ANTIGEN; TUMOR LIBERATED PROTEIN; UNCLASSIFIED DRUG; TUMOR LIBERATED PROTEIN, HUMAN;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; GEL FILTRATION CHROMATOGRAPHY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; IN VIVO STUDY; ISOELECTRIC FOCUSING; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOCYTE TRANSFORMATION; MOLECULAR WEIGHT; PEROXIDASE ANTIPEROXIDASE COMPLEX; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; REVIEW; ARTICLE; GENETICS; LUNG TUMOR; METABOLISM; TUMOR CELL LINE;

ANTIGENS, NEOPLASM; CELL LINE, TUMOR; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS;

EID: 69249223437     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21851     Document Type: Review

References (31)

1. Bernard P, Sinibaldi-Vallebona P, Rasi G, Guarino E, Guadagni F,Garaci E. 1998. Immunisation with TLP (a new tumor associated antigen) induces CTL activity in syngeneic rats. Anticancer Res 18:4990-4994.
2. Diederich S. 2003. Screening for early lung cancer with low-dose spinal computer tomography. Lancet 362:588-589.
3. Esposito C, Tarro G, Cuomo N, Morelli F. 1997. Anti-TLP antibodies in lung cancer patients. Int Med 5:191-194.
4. Finn OJ. 2008. Molecular origins of cancer: Cancer immunology. N Engl J Med 358:2704-2715.
5. Garaci E, Sinibaldi P, Rasi G. 1996. A new tumor-associated-antigen of non-small cell lung cancer: Tumor liberated protein (TLP) a possible tumor marker. Anticancer Res 16:2253-2256.
6. Herberman RB. 1997. Immunotherapy: Where we are and how to proceed. In: Croce CM, Giordano GG, editors. Gene targets for cancer treatment. Naples: Doctor's Acta. pp. 14-15.
7. Hollinshead AC, Stewart THM. 1979. Specific active immunotherapy and specific active immunoprophylaxis in lung cancer In: Moore editor. Advances in medical oncology research and education. 6. Basis for cancer therapy, part 2. New York: Pergamon Press. pp. 85-94.
8. Hollinshead AC, Mc Cammon JH, Yohn DS. 1972. Immunogenicity of a soluble transplantation antigen from adenovirus 12-induced tumor cells demonstrated in inbred hamsters (PD-4). Can J Microbiol 18:1365-1369.
9. Hollinshead AC, Stewart THM, Takita H. 1978. Tumor associated antigens: Their usefulness as biological drugs. In: Muggia F, Rosenzweig M, editors. Lung cancer progress in therapeutic research. New York: Raven Press. pp. 501-518.
10. Murphy G, Tjoia B,Radge H, Kenny G, Boynton A. 1996. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 29:371-380.
11. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. 1998. Vaccination of melanoma patientswith peptide-02 tumor lysate-pulsed dendritic cells. Nat Med 4:328-332.
12. Pederzini A, Guerra GP. 1971 Preliminary clinical results of antineoplastic immunotherapy associated with cytostatic treatments. Boll J St Sieroter Milan 50:268-276.
13. Perna A, Tarro G, Esposito C, Baldi C, Annunziata S, Morelli F, Cuomo N, Di Spirito A. 1999. Neoangiogenesis and prognosis in lung cancer. Int Med 7:111-113.
14. Perna A, Tarro G, Perna F, Esposito C. 2001. Immunochemical evaluation of endotelial damage by angioinvasivity. Int J Clin Invest 9:31-33.
15. Prager MD, Hollinshead AC, Ribble HJ, Dera I. 1973. Immunity induction by multiple methods, including soluble membrane fractions to a mouse lymphoma. J Natl Cancer Inst 51:1607.
16. Rasi G, Sinibaldi-Vallebona P, Serafino A, Bernard P, Pierimarchi P, Guarino E, Faticanti- Scucchi L, Graziano P, Guadagni F, Garaci E. 2000. A new human tumor-associated antigen (TLP) is naturally expressed in rat DHD-K12 colorectal tumor cells. Int J Cancer 85:540-5544.
17. Rennik BE. 1979. Cancer immunotherapy: Facts and fancy. J Clin 29:362-365.
18. Schiller JH. 2008. Noninvasive monitoring of tumor. N Engl J Med 359:418-420.
19. Tarro G. 1991. Present and future of cancer immunotherapy: Sagripanti A, GagliardiC,Carpi A, Tarro G, editors. Progress in Medicine and Surgery, Proc. Nat. Meeting, San Romano (Pisa) 13 April 1991, pp. 181-186, ETS, Publisher, Pisa.
20. Tarro G. 1999. Tumor liberated protein (TLP). Its potential for diagnosis and therapy. Anticancer Res 19:1755-1758.
21. Tarro G. 2000. An overview of the lung tumor liberated protein (TLP). Characterization of the genetic immunologic profile. Int Med 8:5-8.
22. Tarro G. 2002. Characterization of a fragment containing a putative TLP cDNA sequence. Anticancer Res 22:2693-2696.
23. Tarro G, Esposito C. 2002. Progress and new hope in the fight against cancer: Novel developments in early detection of lung cancer. Int Med 10:7-11.
24. Tarro G, Pederzini A. 1982. Some considerable immunogenic proprieties of an antigenic set obtained from neoplastic tissue (TLP). Folia Oncol 5:19-32.
25. Tarro G, Pederzini A, Flaminio G, Maturo S. 1983. Human tumor antigens inducing in vivo delayed hypersensitivity and in vitro mitogenic activity. Oncology 40:248-254.
26. Tarro G, Marshak DR, Perna A, Esposito C. 1993. Antigenic regions of tumor liberated protein complexes and antibodies against the same. In: Carpi A, Sagripanti A, Grassi B, editors. Third International Congress. Advances in Management of Malignancies. Pisa, Italy: 6/10 December 1993. Biomed Pharmacother 47: 237-240.
27. Tarro G, Esposito C, Perna A, Claudio PP, Giordano A. 1998. Immunoistochemical characterization of tumor liberated particles (TLP) expression pattern in lung cancer. Anticancer Res 18:2365-2370.
28. Tarro G, Esposito C, Perna A, Cuomo N, Di Spirito A, Morelli F, Perna F, Maio A, Nolli ML. 2001. Production and characterization of anti-TLP derived peptide (RTNKEASIC) monoclonal antibodies. Int Med 9:55-61.
29. Tarro G, Perna A, Esposito C. 2005. Early diagnosis of lung cancer by detection of tumor liberated protein. J Cell Physiol 2005:1-5.
30. Van der Gaast A, Shoenmarkers CHH. 1994. Evalution of a new tumor marker in patients with non-small-cell-lung cancer: Cyfra 21-21. Br J Cancer 69: 525-528.
31. Weiss DW. 1980. Tumor antigenicity and approaches to tumor immunotherapy. An outline. In: Current topics in microbiology and immunology. Berlin, Heidelberg, New York: Springer Verlag.